Intensity Therapeutics, Inc.
INTS
$3.70
-$0.04-1.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.81% | 1.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.89% | 1.04% | |||
| Operating Income | -14.89% | -1.04% | |||
| Income Before Tax | -14.23% | -5.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.23% | -5.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.23% | -5.28% | |||
| EBIT | -14.89% | -1.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 15.59% | 53.85% | |||
| Normalized Basic EPS | 15.58% | 53.85% | |||
| EPS Diluted | -68.94% | 53.85% | |||
| Normalized Diluted EPS | 15.58% | 53.85% | |||
| Average Basic Shares Outstanding | 35.32% | 128.13% | |||
| Average Diluted Shares Outstanding | 35.32% | 128.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||